z-logo
Premium
microRNA‐183 improve myocardial damager via NF‐kb pathway: In vitro and in vivo study
Author(s) -
Xing Jie,
Xie Ting,
Tan Wei,
Li Ruzheng,
Yu Cheng,
Han Xiaohu
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.28298
Subject(s) - in vivo , apoptosis , microbiology and biotechnology , terminal deoxynucleotidyl transferase , western blot , microrna , flow cytometry , staining , h&e stain , in vitro , immunohistochemistry , cell , chemistry , biology , andrology , pathology , tunel assay , immunology , biochemistry , medicine , gene , genetics
Aim The aim of this study is to evaluate the effects of microRNA‐183 (miRNA‐183) in myocardial damager. Methods In the cell experiment, the H9C2 cell was divided into three groups: NC group, Model group, and miRNA group. The cell apoptosis and relative proteins’ expressions were measured by flow cytometry and Western blot assay. The in vivo study of the rats was divided into three groups: Sham group, Model group, and miRNA group. The pathology, Infarct size, cell apoptosis, and relative protein expressions were evaluated by hematoxylin and eosin staining, nitro blue tetrazolium staining, terminal deoxynucleotidyl transferase dUTP nick‐end labeling assay, and immunohistochemistry. Results Compared with NC groups, the in vitro and in vivo study showed that cell apoptosis rate of miRNA groups was significantly suppressed ( P < 0.05). The pathology and infarct size of miRNA group were significantly improved compared with the NC group. Meanwhile, the relative proteins expression (nuclear factor‐κB [NF‐kb], caspase‐3, Bax, and Bcl‐2) of miRNA groups were significantly different compared with those of NC groups ( P < 0.05). Conclusion In vitro and in vivo study revealed that miRNA‐183 improves myocardial damager through the NF‐κb pathway.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here